5% minoxidil: treatment for female pattern hair loss.
5% minoxidil: treatment for female pattern hair loss. Skin Therapy Lett. 2014 Dec;19(6):5-7 Authors: Gupta AK, Foley KA Abstract Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. While 5% minoxidil foam has been approved for men since 2006, Health Canada and the FDA only approved 5% minoxidil foam for female pattern hair loss (FPHL) in 2014. Recent Phase III clinical trials demonstrated the efficacy of once daily 5% minoxidil foam for treatment of FPHL, where a significant change from baseline in the target area hair count was observed compared to placebo. Similar changes in hair count for 5% foam and twice daily 2% minoxidil solution established noninferiority of the 5% foam formulation. Five percent minoxidil foam provides an additional option for women with FPHL and will soon be available in Canada. PMID: 25807073 [PubMed - in process]
The Norwood scale is a system of classification for the stages of male pattern baldness. Read this article to learn about the stages of the Norwood scale and how it can help the treatment of hair loss.
Authors: Gupta AK, Carviel JL Abstract Background: Alopecia areata (AA) is an autoimmune disease that can result in spontaneous hair loss. Currently, there is no US Food and Drug Administration (FDA) approved treatment, however new treatments are being investigated. Excimer laser and excimer lamp treatment have been suggested and have the benefit of mild/few adverse effects.Methods: A literature search and meta-analysis was performed to investigate the efficacy of the excimer laser and lamp for treatment of AA. Results: No controlled trials were found which utilized the 308-nm excimer lamp. Four controlled trials (...
Publication date: Available online 13 November 2019Source: Clinica Chimica ActaAuthor(s): Xin Zeng, Yuan-jie Xie, Ya-ting Liu, Shuang-lian Long, Zhong-cheng MoAbstractPolycystic ovary syndrome (PCOS) is a complex and heterogeneous endocrine disease characterized by clinical or laboratorial hyperandrogenism, oligo-anovulation and metabolic abnormalities, including insulin resistance, excessive weight or obesity, type II diabetes, dyslipidemia and an increased risk of cardiovascular disease. The most significant clinical manifestation of PCOS is hyperandrogenism. Excess androgen profoundly affects granulosa cell function and...
Accutane, a drug that helps treat severe acne, contains isotretinoin. Isotretinoin may cause side effects, including hair loss. Learn more about why Accutane may cause hair loss, and some ways to counter it, here.
ConclusionAnticoagulants used in PRP preparation affected patients ’ pain perceptions during the injections. The sensation of pain with PRP prepared with Na-citrate as an anticoagulant was lower than that of PRP prepared with ACD-A. Further studies are required to evaluate the correlation between anticoagulants used for PRP preparation and pain feelings during in jections.Level of Evidence IIIThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authorswww.springer.com/00266.
Dandruff itself does not cause hair loss, but the two may be linked, as some infections and medical conditions can cause both dandruff and hair loss. Learn more about dandruff, hair loss, and prevention here.
Adenosine is a locally produced mediator exerting several cytoprotective effects via G-protein coupled cell membrane adenosine receptors (ARs) (Linden 2005). In the skin, adenosine can influence several (patho)physiological processes, such as wound healing, development of scleroderma, cutaneous inflammation, allergic reactions or barrier formation (Andr és et al. 2017; Burnstock et al. 2012; Silva-Vilches et al. 2019). A beneficial effect of adenosine on hair growth has already been reported in clinical studies: topical adenosine treatment was shown to alleviate the symptoms of alopecia by increasing hair thickness ...
ConclusionsThe efficacy and safety of LEN in the Japanese population were similar to those in the overall population of REFLECT. With manageable adverse events, LEN is a new treatment option for Japanese patients with uHCC.Trial registration IDClinicalTrials.gov. No. NCT01761266.
Publication date: Available online 10 November 2019Source: Actas Dermo-Sifiliográficas (English Edition)Author(s): C. Pindado-Ortega, D. Saceda-Corralo, S. Vañó-Galván
Hair loss is a side effect of certain medications. Read on to find out which medications can cause hair loss. We also provide tips on how to prevent and reverse hair loss.